Structure attributes must be viewed using STN Express query preparation.

}.

=> s l1 SAMPLE SEARCH INITIATED 17:27:05 FILE 'REGISTRY' SAMPLE SCREEN SEARCH COMPLETED - 119 TO ITERATE

100.0% PROCESSED 119 ITERATIONS 1 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*

BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 1726 TO 3034

PROJECTED ANSWERS: 1 TO 80

L2 1 SEA SSS SAM L1

=> s l1 sss full FULL SEARCH INITIATED 17:27:20 FILE 'REGISTRY' FULL SCREEN SEARCH COMPLETED - 2285 TO ITERATE

100.0% PROCESSED 2285 ITERATIONS 42 ANSWERS

SEARCH TIME: 00.00.01

L3 42 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS
SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST
148.36

FILE 'CAPLUS' ENTERED AT 17:27:24 ON 10 APR 2003 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing

Habte 4/8/2003

of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 10 Apr 2003 VOL 138 ISS 15 FILE LAST UPDATED: 9 Apr 2003 (20030409/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 13

L4 6 L3

=> d ibib abs hitstr tot

Habte 4/8/2003

L4 ANSWER 1 OF 6
ACCESSION NUMBER:
DOCUMENT NUMBER:
TITLE:

INVENTOR(S):
PATENT ASSIGNEE(S):

CAPLUS COPYRIGHT 2001 ACS
ACO2:717059 CAPLUS
CAPTURE 247710
Preparation of aryl phenylheterocyclyl sulfides as cell adhesion-inhibiting anti-inflammatory and immune-suppressive agents
Mang. Gary T.; Wang. Sheldon; Gentles, Robert
USA

INVENTOR (S): PATENT ASSIGNEE (S): SOURCE:

U.S. Pat. Appl. Publ., 44 pp. CODEN: USXXCO Patent English

DOCUMENT TYPE: LANGUAGE: FAMILY ACC. NUM. COUNT: PATENT INFORMATION:

APPLICATION NO. PATENT NO. KIND DATE DATE ----US 2002132807
PRIORITY APPLN. INFO.:
OTHER SOURCE(S):
GI A1 20020919 US 2001-888840 20010625 2000-214983P P 20000629 US 2000-214983P MARPAT 137:247710

The title compds. [I; R1-R5 = H, halo, alkyl, etc. (with proviso that at least one of R1 or R3 = (un)substituted pyridyl, pyrimidyl, oxazolyl, etc.); A = (un)substituted aryl, heterocyclyl) were prepd. for treating inflammatory and immune diseases, such as arthritis, asthma, reperfusion injury, inflammatory bowel disease etc. The products I had IC50 <20

RE: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(Uses)
(prepn. of aryl phenylheterocyclyl sulfides as cell adhesion-inhibiting

ANSWER 1 OF 6 CAPLUS COPYRIGHT 2003 ACS

388117-67-7 CAPLUS
4-Piperidinecarboxamide, 1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

188117-68-8 CAPLUS
Acetamide, N-ethyl-N-[1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]-3-pyrrolidinyl]- (9CI) (CA INDEX

388117-69-9 CAPLUS
3-Piperidinecarboxylic acid, 1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]-, ethyl ester (9CI) (CA INDEX

ANSWER 1 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)
antiinflammatory and immunosuppressive agents)
388117-63-3 CAPLUS
Morpholine, 4-[6-[4-[[2-(1-methylethyl]phenyl]thio]-3(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

388117-64-4 CAPLUS
4-Piperidinol, 1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

388117-65-5 CAPLUS Morpholine, 2,6-dimethyl-4-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

388117-66-6 CAPLUS
3-Piperidinecarboxamide, 1-[6-[4-[(2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl)- (9CI) (CA INDEX NAME)

ANSWER 1 OF 6 CAPLUS COPYRIGHT 2003 ACS

388117-70-2 CAPLUS
4-Piperidinecarboxylic acid, 1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]-, ethyl ester (9CI) (CA INDEX NAME)

388117-71-3 CAPLUS
1-Piperazinecarboxylic acid, 4-{6-{4-{[2-{1-methylethyl]phenyl}thio}-3-{trifluoromethyl}phenyl}-4-pyrimidinyl}-, ethyl ester {9CI} (CA INDEX NAME)

388117-72-4 CAPLUS
1-Piperazineacetic acid, 4-[6-[4-([2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]-, ethyl ester (9CI) (CA INDEX NAME)

ANSWER 1 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)

. CH2-C-0Et

388117-73-5 CAPLUS
4-Pyrimidinamine, N-[3-(1H-imidazol-1-yl)propyl)-6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

388117-74-6 CAPLUS
4-Piperidinecarboxylic acid, 1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

388117-75-7 CAPLUS
3-Piperidinecarboxylic acid, 1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

ANSWER 1 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)

388117-79-1 CAPLUS
Pyrimidine, 4-[4-[[2-(1-methylethyl)phenyl]thio]-3(trifluoromethyl)phenyl]-6-[4-(1H-tetrazol-5-yl)-1-piperidinyl]- (9CI)
(CA INDEX NAME)

388117-80-4 CAPLUS
3-Piperidinemethanol, 1-{6-{4-{{2-(1-methylethyl)phenyl}thio}-3-(trifluoromethyl)phenyl}-4-pyrimidinyl}- (9CI) (CA INDEX NAME)

388117-81-5 CAPLUS
4-Piperidineethanol, 1-[6-[4-[[2-[1-methylethyl]phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

388117-82-6 CAPLUS
Acetamide, N-{1-{6-{4-{{2-(1-methylethyl)phenyl}thio}-3-(trifluoromethyl)phenyl}-4-pyrimidinyl}-3-pyrrolidinyl}- (9CI) (CA INDEX NAME)

ANSWER 1 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)

388117-76-8 CAPLUS
Pyrimidine, 4-[4-[(2-(1-methylethyl)phenyl]thio]-3(trifluoromethyl)phenyl]-6-[4-(2-pyridinyl)-1-piperazinyl]- (9CI) (CA

388117-77-9 CAPLUS
3-Piperidinecarboxamide, N,N-diethyl-1-[6-{4-{[2-(1-methyl-thyl]phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

388117-78-0 CAPLUS
Pyrimidine, 4-[4-[[2-(1-methylethyl)phenyl]thio]-3(trifluoromethyl)phenyl]-6-(3-(1H-tetrazol-5-yl)-1-piperidinyl]- (9CI)
(CA INDEX NAME)

ANSWER 1 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)

388117-83-7 CAPLUS Pyrimidine,  $4-[(2R)-2-(methoxymethyl)-1-pyrrolidinyl]-6-[4-[{2-(1-methylethyl)phenyl}]+10]-3-(trifluoromethyl)phenyl)- (9CI) (CA INDEX NAME)$ 

Absolute stereochemistry

388117-84-8 CAPLUS
3-Pyrrolidinol, 1-{6-[4-{[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl)-4-pyrimidinyl]-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

ANSWER 1 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)

388117-85-9 CAPLUS
Carbamic acid, [1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3tiriluoromethyl)phenyl]-4-pyrimidinyl}-3-pyrrolidinyl}-,
1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

 $388117-86-0 \quad CAPLUS \\ 4-Pyrimidinamine, N-methyl-N-(1-methylethyl)-6-[4-[(2-(1-methylethyl)phenyl]thiol-3-(trifluoromethyl)phenyl] \quad (CA INDEX \\ 10-(CA INDEX - 1-(1-methylethyl)phenyl) - (CA INDEX - 1-(1-methylethyl)phenyl) - (CA INDEX - 1-(1-methyl)phenyl) - (CA INDEX - 1-(1-methylethyl)phenyl) - (CA INDEX - 1-(1-methylethyl)phenyl)phenyl) - (CA INDEX - 1-(1-methylethyl)phenyl)phenyl) - (CA INDEX - 1-(1-methylethyl)phenyl)phenyl)phenyl)phenyl$ 

ANSWER 1 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)

ANSWER 1 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)

RN 388117-87-1 CAPLUS CN 4-Pyrimidinamine, N-ethyl-N-methyl-6-[4-[{2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl}- (9CI) (CA INDEX NAME)

$$\underbrace{ \begin{array}{c} i \cdot Pr \\ S \\ CF_3 \end{array} }$$

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (Reactant or r

38818-57-8 CAPLOS (4(1H)-Pyrimidinone, 6-[4-[(2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

388118-58-9 CAPLUS
Pyrimidine, 4-chloro-6-[4-[[2-(1-methylethyl)phenyl]thio]-3(trifluoromethyl)phenyll- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2002:449662 CAPLUS
DOCUMENT NUMBER: 137:33310
ITITLE: PROPERTIES (Kois, Adam; MacFarlane, Karen J.; Satoh, Yoshitaka; Bhagwat, Shripad S.; Parnea, Jason S.; Palanki, Moorthy S. S.; Edman, Paul E.
SOURCE: Signal Pharmaceuticale, Inc., USA
CODENT TYPE: CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
English

FAMILY ACC. NUM. COUNT: PATENT INFORMATION:

PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE

WO 2002046171 A2 20020613 WO 2001-US46403 20011205

WO 2002046171 A3 20030123

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EE, FI, GB, GD, GE, GH, GM, HR, HU, ID, LL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MN, MX, MZ, NO, NZ, CM, PH, FL, PT, RO, RU, SD, SS, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RH: GH, GM, KE, LS, MM, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
AU 2002020195 A5 20020618 AU 2001-US46403 W 20011205

OTHER SOURCE(S): MARPAT 137:33310

AB The title compds. [I; R1 = (un) substituted (hetero) aryl; R2 = H; R3 = H, alkyl; R4 = halo, OH, alkyl, alkoxy; R5, R6 = R8, (CH2) acozR9, etc.; or NR5R6 = (un) substituted heterocycle; R8, R9 = H, alkyl, aryl, etc.; a = 0.4) having activity as inhibitors of IKK, particularly IKK-2, were prepd. E.g., a multi-step synthesis of I [R1 = 4-ClC6H4; R2-R6 = H] having an ICSO of .ltoreq. 1 .mu.M in the IKK-2 enzyme assay, was given. Such compds. I have utility in the treatment of a wide range of conditions

that are responsive to IKK inhibition. Thus, methods of treating such conditions are also disclosed, as are pharmaceutical compns. contg. one

more compds. of the above compds. 434944-90-8P 434945-04-7P 434945-05-8P 434945-27-4P 434950-45-5P 434950-46-6P IТ

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)
434950-47-7P 434950-68-8P 434950-49-9P
434950-50-2P 434950-51-3P 434950-52-4P
434950-53-5P
RL: PAC (Pharmacological activity); SFN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Usea)
(prepn. of anilinopyrimidines as IKK inhibitors)
RN 43494-90-8 CAPLUS
CN Benzamide.
4-[[4-[4-(d-chlorophenyl) sulfonyl) phenyl]-2-pyrimidinyl]amino](9CI) (CA INDEX NAME)

434945-04-7 CAPLUS Benzamide, 4-[[4-[4-(phenylthio)phenyl]-2-pyrimidinyl]amino]- (9CI) (CAINDEX NAME)

434945-05-8 CAPLUS
Benzamide, 4-[[4-[4-(phenylsulfonyl)phenyl]-2-pyrimidinyl]amino]- (9CI)
(CA INDEX NAME)

434945-27-4 CAPLUS
Morpholine, 4-[4-[4-[4-(phenylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)

ANSMER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)
434950-48-8 CAPLUS
Piperazine, 1-(2-furanylcarbonyl)-4-[4-[[4-[4-(phenylaulfonyl)phenyl]-2pyrimidinyl]aminojbenzoyl]- (9CI) (CA INDEX NAME)

434950-49-9 CAPLUS
Piperazine, 1-methyl-4-[4-[4-[4-(phenylsulfonyl)phenyl]-2pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)

434950-50-2 CAPLUS
Piperazine, 1-[4-[4-[4-[qhenylsulfonyl)phenyl]-2pyrimidinyl]amino|benzoyl]-, dihydrochloride (9CI) (CA INDEX NAME)

●2 HCl

434950-51-3 CAPLUS CN 1-Piperazinepropanamine,
N,N-dimethyl-4-(4-[4-[4-(4-(phenylsulfonyl)phenyl]2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)

ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued) Ph-

434950-45-5 CAPLUS
Piperazine, 1-(2-ethoxyethyl)-4-[4-[[4-[4-(phenylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl)- (9CI) (CA INDEX NAME)

434950-47-7 CAPLUS
Piperazine, 1-acetyl-4-[4-([4-(4-(phenylsulfonyl)phenyl]-2pyrimidinyl]amino|benzoyl]- (9CI) (CA INDEX NAME)

ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS

434950-52-4 CAPLUS
Benzamide, N-(4-hydroxycyclohexyl)-4-[{4-[4-(phenylsulfonyl)phenyl]-2pyrimidinyl]aminoj- (9CI) (CA INDEX NAME)

434950-53-5 CAPLUS Benzamide, N.-dimethyl-4-[[4-[4-(phenylsulfonyl)phenyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER:
DOCUMENT NUMBER:
137:33309
Preparation of anilinopyrimidines as JNK pathway inhibitors
INVENTOR(S):
KOIS, Adam; MacFarlane, Karen J.; Satoh, Yoshitaka; Bhagwat, Shripad S.; Parnen, Jason S.; Palanki, Moorthy S. S.; Erdman, Paul E.
SURCE:
PATENT ASSIGNEE(S):
SOURCE:
POCUMENT TYPE:
DOCUMENT TYPE:
DOCUMENT TYPE:
LANGUAGE:
PATENT
LANGUAGE:
English

DOCUMENT TYPE: English PAMILY ACC. NUM. COUNT: PATENT INFORMATION:

PATENT NO. PATENT NO. KIND DATE

WO 2002046170 A2 20020613 W0 2001-US46402 20011205

W: AE, AG, AL, AM, AT, AL, AZ, BA, BB, BG, RR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MM, MM, MX, MZ, NO, NZ, OM, PH, PL, FT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, AZ, AM, AZ, MA, AZ, BY, KG, KZ, MD, RU, TJ, TM, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, AU 2002027214 A5 20020618

PRIORITY APPLN. INFO:

WARPAT 137:33309 KIND DATE APPLICATION NO. DATE

OTHER SOURCE(S):

AB The title compds. [I; Rl = (un)substituted (hetero)aryl; R2 = H; R3 = H, alkyl; R4 = halo, OH, alkyl, alkoxy; R5, R6 = R8, (CH2)acOR9, etc.; or NRSR6 = (un)substituted heterocycle; R8, R9 = H, alkyl, aryl, etc.; a = 0.4] having activity as inhibitors of the JNK pathway, were prepd. E.g., a multi-step synthesis of I [R1 = 4-ClC6H4; R2-R6 = H] having an ICSO of .ltoreq. 10. mu. Min the JNK2 assay, was given. Such compds. I have utility in the treatment of a wide range of conditions that

are responsive to inhibition of the JNK pathway. Thus, methods of treating such conditions are also disclosed, as are pharmaceutical

ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued) pyrimidinyl]amino|benzoyl]- (9CI) (CA INDEX NAME)

434950-45-5 CAPLUS
Piperazine, 1-(2-ethoxyethyl)-4-[4-([4-(4-(phenylsulfonyl)phenyl]-2-pyrimidinyl]aminolbenzoyl]- (9CI) (CA INDEX NAME)

434950-46-6 CAPLUS
Piperazine, 1-[4-[4-(4-(phenylsulfonyl)phenyl]-2pyrimidinyl]amino]benzoyl]-4-[(tetrahydro-2-furanyl)methyl]- (9CI) (CA
INDEX NAME)

434950-47-7 CAPLUS
Piperazine, 1-acetyl-4-[4-[4-[4-(phenylsulfonyl)phenyl]-2pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)

434950-48-8 CAPLUS

Habte

ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Contg. one or more compds. of the above compds. 414944-90-89 434945-04-7P 434945-05-8P 434950-46-FP 434950-46-FP 434950-47-P 434950-48-8P 434950-49P 434950-52-4P 434950-53-5P (Continued) RL: PAC (Phermacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (prepn. of anilinopyrimidines as JNK pathway inhibitors) 434944-90-8 CAPLUS

Benzamide. [4-[(4-chlorophenyl)sulfonyl)phenyl)-2-pyrimidinyl]amino](9CI) (CA INDEX NAME)

434945-04-7 CAPLUS Benzamide, 4-[[4-[4-(phenylthio)phenyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

434945-05-8 CAPLUS Benzamide, 4-[[4-[4-(phenyleulfonyl)phenyl]-2-pyrimidinyl]amino]- (9CI)

434945-27-4 CAPLUS Morpholine, 4-[4-[4-[4-(phenylsulfonyl)phenyl]-2-

ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)
Piperazine, 1-(2-furanylcarbonyl)-4-[4-[(4-[4-(phenylsulfonyl)phenyl]-2pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)

434950-49-9 CAPLUS
Piperazine, 1-methyl-4-[4-[4-[4-[qhenylsulfonyl)phenyl]-2pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)

434950-50-2 CAPLUS
Piperazine, 1-[4-[4-[4-(phenylsulfonyl)phenyl]-2pyrimidinyl]aminolbenzoyl]-, dihydrochloride (9CI) (CA INDEX NAME)

●2 HC1

RN 434950-51-3 CAPLUS
CN 1-Piperszinepropanamine,
N,N-dimethyl-4-[4-(14-(4-(phenylsulfonyl)phenyl]2-pyrimidinyl]amino|benzoyl]- (9CI) (CA INDEX NAME)

ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)

434950-52-4 CAPLUS Benzamide, N-(4-hydroxycyclohexyl)-4-[{4-{4-(phenylsulfonyl)phenyl}-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

434950-53-5 CAPLUS
Benzamide, N,N-dimethyl-4-{[4-{4-(phenylsulfonyl)phenyl}-2-pyrimidinyl]amino}- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)
(prepn. of aryl phenylheterocyclyl sulfides as cell
adhesion-inhibiting
antiinflammatory and immunosuppressive agents)
RN 388118-57-8 CAPLUS
CN 4(1H)-Pyrimidinome, 6-[4-[[2-(1-methylethyl)phenyl]thio]-3(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

388118-58-9 CAPLUS
Pyrimidine, 4-chloro-6-[4-{[2-(1-methylethyl)phenyl]thio]-3{trifluoromethyl)phenyl}- (9CI) (CA INDEX NAME)

388117-64-4 CAPLUS 4-Piperidinol, 1-[6-[4-([2-(1-methylethyl)phenyl]thio]-3-

Habte

L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS ACCESSION NUMBER: 2002:31429 CAPLUS DOCUMENT NUMBER: 136:102394

Aryl phenylheterocyclyl sulfide derivatives and their use as cell adhesion-inhibiting anti-inflammatory and immune-suppressive agents
Wang, Gary T.; Wang, Sheldon; Gentles, Robert
Abbott Lab., USA
PCT Int. Appl., 135 pp.
CODEN: PIXXD2
Patent DOCUMENT NUMBER: TITLE:

INVENTOR(S):
PATENT ASSIGNEE(S):
SOURCE:

DOCUMENT TYPE: LANGUAGE: FAMILY ACC. NUM. COUNT: PATENT INFORMATION: Patent English

PATENT NO. KIND DATE APPLICATION NO. DATE 

MARPAT 136:102394 OTHER SOURCE(S):

Title compds. were prepd. for treating inflammatory and immune diseases, such as arthritis, asthma, reperfusion injury, inflammatory bowel disease etc. The products had IC50 <20 mM for inhibition of ICAM-1 binding to LFA-1. 2-Me2CHG6H4SHwas etherified with 4,3-F(F3C)C6H3COMe, followed by bromination, and reaction with 1-carbamoylpiperidine to give the sulfide

1. 388118-57-8P 388118-58-9P RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued) (trifluoromethyl)phenyl)-4-pyrimidinyl)- (9CI) (CA INDEX NAME)

388117-65-5 CAPLUS
Morpholine, 2,6-dimethyl-4-[6-[4-[{2-{1-methylethyl}phenyl}thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl}- (9CI) (CA INDEX NAME)

388117-66-6 CAPLUS
3-Piperidinecarboxamide, 1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

388117-67-7 CAPLUS
4-Piperidinecarboxamide, 1-[6-[4-[(2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl)-4-pyrimidinyl)- (9CI) (CA INDEX NAME)

ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued) 388117-68-8 CAPLUS ACCEAMIGE, N-ethyl-N-[1-[6-[4-[2-(1-methylethyl]phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]-3-pyrrolidinyl]- (9CI) (CA INDEX

388117-69-9 CAPLUS
3-Piperidinecarboxylic acid, 1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]-, ethyl ester (9CI) (CA INDEX

388117-70-2 CAPLUS 4-Piperidinecarboxylic acid, 1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]-, ethyl ester (9CI) (CA INDEX

ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS

388117-74-6 CAPLUS
4-Piperidinecarboxylic acid, 1-{6-[4-[(2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

388117-75-7 CAPLUS
3-Piperidinecarboxylic acid, 1-[6-[4-[(2-(1-methylethyl)phenyl]thio]-3(crifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

388117-76-8 CAPLUS
Pyrimidine, 4-[4-[[2-(1-methylethyl)phenyl]thio]-3(trifluoromethyl)phenyl]-6-[4-(2-pyridinyl)-1-piperazinyl]- (9CI) (CA
INDEX NAME)

ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS

388117-71-3 CAPLUS
1-Piperazinecarboxylic acid, 4-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]-, ethyl ester (9CI) (CA INDEX

388117-72-4 CAPLUS
1-Piperazineacetic acid, 4-[6-[4-[(2-(1-methylethyl)phenyl]thio]-3[trifluoromethyl)phenyl]-4-pyrimidinyl]-, ethyl ester (9CI) (CA INDEX

388117-73-5 CAPLUS
4-Pyrimidinamine, N-[3-(1H-imidezol-1-yl)propyl]-6-[4-[[2-{1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)

388117-77-9 CAPLUS
3-Piperidinecarboxamide, N,N-diethyl-1-[6-[4-[[2-(1-methyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI)
(CA INDEX NAME)

388117-78-0 CAPLUS
Pyrimidine, 4-[4-{[2-(1-methylethyl)phenyl]thio]-3(trifluoromethyl)phenyl]-6-[3-(1H-tetrazol-5-yl)-1-piperidinyl]- (9CI)
(CA INDEX NAME)

CN

388117-79-1 CAPLUS
Pyrimidine, 4-[4-{[2-(1-methylethyl)phenyl]thio]-3(trifluoromethyl)phenyl)-6-[4-(1H-tetrazol-5-yl)-1-piperidinyl]- (9CI)
(CA INDEX NAME)

ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)
388117-80-4 CAPLUS
3-Piperidinemethanol, 1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(crifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

388117-81-5 CAPLUS 4-Piperidineethanol, 1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(rrifluoromethyl)phenyl]-4-pyrimidinyl)- (9CI) (CA INDEX NAME)

388117-82-6 CAPLUS
Acetamide, N-[1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3(trifluoromethyl)phenyl]-4-pyrimidinyl]-3-pyrrolidinyl]- (9CI) (CA INDEX

388117-83-7 CAPLUS
Pyrimidine, 4-[(2R)-2-(methoxymethyl)-1-pyrrolidinyl]-6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAMF) RN CN

L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS Absolute stereochemistry.

388117-84-8 CAPLUS
3-Pyrrolidinol, 1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3(trifluoromethyl)phenyl]-4-pyrimidinyl]-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

388117-85-9 CAPLUS Carbamic acid, [1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]-3-pyrrolidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS

388117-86-0 CAPLUS
4-Pyrimidinamine, N-methyl-N-(1-methylethyl)-6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

RN 388117-87-1 CAPLUS CN 4-Pyrimidinamine, N-ethyl-N-methyl-6-(4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE REFERENCE COUNT:

L4 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2003 ACS ACCESSION NUMBER: 1992:612432 CAPLUS DOCUMENT NUMBER: 117:212432 117:212432
Studies on cerebral protective agents. I. Novel
4-arylpyrimidine derivatives with anti-anoxic and
anti-lipid peroxidation activities
Kuno, Atsushi; Sugiyama, Yoshie; Katsuta, Kiyotaka;
Kamitani, Toshiharu; Takasugi, Hisashi
New Drug Res. Lab., Fujisawa Pharm. Co., Ltd., Osaka,
532, Japan
Chemical & Pharmaceutical Bulletin (1992), 40(6),
1452-61
CODEN: CPBTAL; ISSN: 0009-2363
Journal TITLE: AUTHOR (S): CORPORATE SOURCE: SOURCE: DOCUMENT TYPE:

AB Novel 4-arylpyrimidine derivs, were synthesized by the oxidn. of 4-aryl-1,4-dihydropyrimidines, and their effects on anti-anoxic (AA) activity in mice and anti-lipid peroxidn. (ALP) activity in rat brain mitochondria were investigated. Among these compds, Et 6-methyl-2-phenyl-4-(4-pyridyl) -5-pyrimidinecarboxylate (I, R = 4-pyridyl) has AA activity (10 mg/kg, i.p.) and Et 6-methyl-4-(3-nitrophenyl)-2-phenyl-5-pyrimidinecarboxylate (I, R = 3-020KGH4) has ALP activity (734 inhibition at 10-5 g/mL). The latter compd. (100 mg/kg, i.p.) was also effective on arachidonate-induced cerebral edem in rats with comparable potency to that of vitamin E.

103293-67-0P
RL: SPN (Synthetic preparation); PREP (Preparation) (prepn. antianoxic and antilipid peroxidn. activities of)
RN 103293-67-0 CAPLUS
CN 5-Pyrimidinecarboxylic acid, 4-(2-1(4-chlorophenyl)thio)phenyl]-6-methyl-2-phenyl-, ethyl ester (9CI) (CA INDEX NAME)

4/8/2003

Habte

L4 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)

L4 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1986:572492 CAPLUS
DOCUMENT NUMBER: 105:172492
ITILE: Pyrimidine derivatives
Takyay, Takao; Takasugi, Hieashi; Kuno, Atsushi;
SUSIYama, Yoshie
PHITAMA PHARMARCEUTICAL Co., Ltd., Japan
EUr. Pat. Appl., 192 pp.
DOCUMENT TYPE: Patent
FAMILIANS LANGUAGE: English FAMILY ACC. NUM. COUNT: PATENT INFORMATION: ENT 1...

PATENT NO. KIND DA'L

EP 169712 A2 19860129 EP 1985-305143 -
EP 169712 B1 19901212

R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE

US 4698340 A 19871006 US 1985-753912 IS

2A 8505369 A 19860120 PI 1985-27596 IS

NO 8502869 A 19860120 PI 1985-2766 IS

NO 8502869 A 19860120 DX 1985-2869 IS

ES 455447 A1 198610120 DX 1985-2879 IS

ES 45547 A1 198610120 DX 1985-3279 IS

ES 45547 A1 198610120 DX 1985-3279 IS

ES 456347 A1 198610120 DX 1985-36343 IS

AU 8545202 A1 19860120 DX 1985-36343 IS

AU 8545202 A1 198601215 AT 1985-305143 IS

AU 8545202 A1 198601220 JY 1985-160784 IS

AU 8545202 A1 19860226 JP 1985-160784 IS

AU 8545202 A1 19860226 JP 1985-160784 IS

AU 85463436 B4 199406229 US 1985-7759043 IS

EB 177287 A2 19860223 US 1985-7759043 IS

EP 177287 A2 19860402 PI 1985-3698 IS

EP 177287 A2 19860402 PI 1985-3698 IS

EP 177287 A3 19861126

EP 177287 A3 19861126

EP 177287 A3 19861126

EP 177287 A3 19864104 DX 1985-48143 JP 61087689 A 19860400 DX 1985-3853 IS

ES 47419 A1 19870316 ES 1985-3630 DX 1985-48146 DX 1985-48146 DX 1985-48140 DX 1985-PATENT NO. KIND DATE APPLICATION NO. DATE 19850718 19850711 19850716 19850717 19850718 19850718 19850718 19850718 19850718 19850719 19850923 19850924 19850926 19850927 19850927 19850930 19850930

ANSWER 6 OF 6 CAPLUS COPYRIGHT 2003 ACS

AB Pyrimidines I (R = substituted ary; R. - com., alkanoyl, etc.; R2 = H, aryl, alkyl, etc.; R3 = alkyl, aryl) were prepd., and they showed their usefulness in the treatment of cerebrovascular diseases. Dihydropyrimidine deriv. II was heated with Mno2 to give I (R = com.) Pyrimidines I (R = substituted aryl; R1 = CO2H, esterified CO2H, Dihydropyrimidine deriv. II was heated with MnO2 to give I (R - 4-pyridy),
R1 = CO2Et, R2 = Me, R3 = Ph). II was prepd. from an .alpha.(arylmethylene)acetoacetate ester and an amidine.
IT 103293-67-00
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, for treatment of cerebrovascular disease)
RN 103293-67-0 CAPBUS
CN 5-Pyrimidinecarboxylic acid,
4-[2-[(4-ch)orophenyl)thio]phenyl]-6-methyl-2phenyl-, ethyl ester (9CI) (CA INDEX NAME)

=> log y

COST IN U.S. DOLLARS
SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)
SINCE FILE TOTAL

CA SUBSCRIBER PRICE ENTRY SESSION -3.91 -3.91

STN INTERNATIONAL LOGOFF AT 17:27:58 ON 10 APR 2003

Habte 4/8/2003

Norrow, Search

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details: http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=> Uploading 09888840narrow.str

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR

Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 10:17:53 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 3 TO ITERATE

100.0% PROCESSED 3 ITERATIONS 0 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*

BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 3 TO 163

PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s l1 sss full

FULL SEARCH INITIATED 10:18:02 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 31 TO ITERATE

100.0% PROCESSED 31 ITERATIONS 1 ANSWERS

SEARCH TIME: 00.00.01

L3 1 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS SINCE FILE TOTAL ENTRY SESSION

Habte 4/8/2003

FULL ESTIMATED COST

148.15 148.36

FILE 'CAPLUS' ENTERED AT 10:18:08 ON 08 APR 2003 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 8 Apr 2003 VOL 138 ISS 15 FILE LAST UPDATED: 7 Apr 2003 (20030407/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 13

L4 2 L3

=> d ibib abs hitstr tot

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER:

2002:717059 CAPLUS

DOCUMENT NUMBER:

137:247710

TITLE:

Preparation of aryl phenylheterocyclyl sulfides as

cell adhesion-inhibiting anti-inflammatory and

immune-suppressive agents

INVENTOR(S):

Wang, Gary T.; Wang, Sheldon; Gentles, Robert

PATENT ASSIGNEE(S):

USA

SOURCE:

U.S. Pat. Appl. Publ., 44 pp.

CODEN: USXXCO

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE

US 2002132807 A1 20020919 US 2001-888840 20010625
PRITY APPLN. INFO.: US 2000-214983P P 20000629

PRIORITY APPLN. INFO.: OTHER SOURCE(S):

MARPAT 137:247710

GΙ

AB The title compds. [I; R1-R5 = H, halo, alkyl, etc. (with proviso that at least one of R1 or R3 = (un) substituted pyridyl, pyrimidyl, oxazolyl, etc.); A = (un) substituted aryl, heterocyclyl] were prepd. for treating inflammatory and immune diseases, such as arthritis, asthma, reperfusion injury, inflammatory bowel disease etc. The products I had IC50 <20 .mu.M for inhibition of ICAM-1 binding to LFA-1. 2-Me2CHC6H4SH was etherified with 4,3-F(F3C)C6H3COMe, followed by bromination, and reaction with 1-carbamoylpiperidine to give the sulfide II.

IT 388117-75-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of aryl phenylheterocyclyl sulfides as cell adhesion-inhibiting antiinflammatory and immunosuppressive agents)

RN 388117-75-7 CAPLUS

CN 3-Piperidinecarboxylic acid, 1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER:

2002:31429 CAPLUS

DOCUMENT NUMBER:

136:102394

TITLE:

Aryl phenylheterocyclyl sulfide derivatives and their

use as cell adhesion-inhibiting anti-inflammatory and

immune-suppressive agents

INVENTOR(S):

Wang, Gary T.; Wang, Sheldon; Gentles, Robert

PATENT ASSIGNEE(S):

Abbott Lab., USA

SOURCE:

PCT Int. Appl., 135 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

A1

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

WO 2002002539

PATENT NO. KIND DATE APPLICATION NO. DATE

20020110

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,

WO 2001-US20128 20010622

CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG EP 1294704 20030326 EP 2001-946705 20010622 **A1** AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR PRIORITY APPLN. INFO.: US 2000-606717 A 20000629 WO 2001-US20128 W 20010622

OTHER SOURCE(S): GI

MARPAT 136:102394

CF<sub>3</sub> CHMe<sub>2</sub>

Title compds. were prepd. for treating inflammatory and immune diseases, AB such as arthritis, asthma, reperfusion injury, inflammatory bowel disease 'etc. The products had IC50 <20 mM for inhibition of ICAM-1 binding to LFA-1. 2-Me2CHC6H4SHwas etherified with 4,3-F(F3C)C6H3COMe, followed by bromination, and reaction with 1-carbamoylpiperidine to give the sulfide I.

IT 388117-75-7P

> RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of aryl phenylheterocyclyl sulfides as cell adhesion-inhibiting antiinflammatory and immunosuppressive agents)

388117-75-7 CAPLUS RN

3-Piperidinecarboxylic acid, 1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-CN (trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

REFERENCE COUNT:

THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS 8 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> log y COST IN U.S. DOLLARS

SINCE FILE TOTAL

4/8/2003 Habte

FULL ESTIMATED COST SESSION 9.49 157.85

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE TOTAL ENTRY SESSION CA SUBSCRIBER PRICE -1.30 -1.30

STN INTERNATIONAL LOGOFF AT 10:18:32 ON 08 APR 2003

Habte 4/8/2003





0 ANSWERS

Structure attributes must be viewed using STN Express query preparation.

=> s l1 SAMPLE SEARCH INITIATED 17:33:30 FILE 'REGISTRY' SAMPLE SCREEN SEARCH COMPLETED - 2803 TO ITERATE

35.7% PROCESSED 1000 ITERATIONS INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED) SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*
BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 52886 TO 59234
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s 11 sss full FULL SEARCH INITIATED 17:33:39 FILE 'REGISTRY' FULL SCREEN SEARCH COMPLETED - 55054 TO ITERATE

100.0% PROCESSED 55054 ITERATIONS 107 ANSWERS SEARCH TIME: 00.00.02

L3 107 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS
SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST
148.36

FILE 'CAPLUS' ENTERED AT 17:33:50 ON 10 APR 2003 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching

Habte 4/8/2003

HIT ----- Fields containing hit terms

containing hit terms
HITRN ----- HIT RN and its text modification

its structure diagram

HITIND ----- IC, ICA, ICI, NCL, CC and index field (ST and IT)

HITSTR ----- HIT RN, its text modification, its CA index name, and

HITSEQ ----- HIT RN, its text modification, its CA index name, its structure diagram, plus NTE and SEQ fields
FHITSTR ---- First HIT RN, its text modification, its CA index name, and

databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 10 Apr 2003 VOL 138 ISS 15 FILE LAST UPDATED: 9 Apr 2003 (20030409/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

6 L3 L4=> d ibib abs histr tot 'HISTR' IS NOT A VALID FORMAT FOR FILE 'CAPLUS' The following are valid formats: ABS ----- GI and AB ALL ----- BIB, AB, IND, RE APPS ----- AI, PRAI BIB ----- AN, plus Bibliographic Data and PI table (default) CAN ----- List of CA abstract numbers without answer numbers CBIB ----- AN, plus Compressed Bibliographic Data DALL ----- ALL, delimited (end of each field identified) DMAX ----- MAX, delimited for post-processing FAM ----- AN, PI and PRAI in table, plus Patent Family data FBIB ----- AN, BIB, plus Patent FAM IND ------ Indexing data IPC ----- International Patent Classifications MAX ----- ALL, plus Patent FAM, RE PATS ----- PI, SO SAM ----- CC, SX, TI, ST, IT SCAN ----- CC, SX, TI, ST, IT (random display, no answer numbers; SCAN must be entered on the same line as the DISPLAY, e.g., D SCAN or DISPLAY SCAN) STD ----- BIB, IPC, and NCL IABS ----- ABS, indented with text labels IALL ----- ALL, indented with text labels IBIB ----- BIB, indented with text labels IMAX ----- MAX, indented with text labels ISTD ----- STD, indented with text labels OBIB ----- AN, plus Bibliographic Data (original) OIBIB ----- OBIB, indented with text labels SBIB ----- BIB, no citations SIBIB ----- IBIB, no citations

Habte

=> s 13

Page 5

09/888840

its structure diagram

FHITSEQ ---- First HIT RN, its text modification, its CA index name, its structure diagram, plus NTE and SEQ fields

KWIC ----- Hit term plus 20 words on either side

OCC ----- Number of occurrence of hit term and field in which it occurs

To display a particular field or fields, enter the display field codes. For a list of the display field codes, enter HELP DFIELDS at an arrow prompt (=>). Examples of formats include: TI; TI,AU; BIB,ST; TI,IND; TI,SO. You may specify the format fields in any order and the information will be displayed in the same order as the format specification.

All of the formats (except for SAM, SCAN, HIT, HITIND, HITRN, HITSTR, FHITSTR, HITSEQ, FHITSEQ, KWIC, and OCC) may be used with DISPLAY ACC to view a specified Accession Number. ENTER DISPLAY FORMAT (BIB):end

=> d ibib abs hitstr tot

Habte 4/8/2003

L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2003 ACS ACCESSION NUMBER: 2002:717059 CAPLUS DOCUMENT NUMBER: 137:247710

DOCUMENT NUMBER: TITLE: 137:247710
Preparation of aryl phenylheterocyclyl sulfides as cell adhesion-inhibiting anti-inflammatory and immune-suppressive agents
Wang, Gary T.; Wang, Sheldon; Gentles, Robert

INVENTOR(S):

USA
U.S. Pat. Appl. Publ., 44 pp.
CODEN: USXXCO PATENT ASSIGNEE(S): SOURCE:

DOCUMENT TYPE: Patent

English

FAMILY ACC. NUM. COUNT: PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE A1 20020919 US 2002132807 20010625 US 2001-888840 20010625 2000-214983P P 20000629 PRIORITY APPLN. INFO.: OTHER SOURCE(S): US 2000-214983P MARPAT 137:247710

The title compds. [I; R1-R5 \* H, halo, alkyl, etc. (with proviso that at least one of R1 or R3 - (un)substituted pyridyl, pyrimidyl, oxazolyl, etc.); A \* (un)substituted aryl, heterocyclyl) were prepd. for treating inflammatory and immune diseases, such as arthritis, asthma. reperfusion injury, inflammatory bowel disease etc. The products I had IC50 <20

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

(prepn. of aryl phenylheterocyclyl sulfides as cell adhesion-inhibiting

ANSWER 1 OF 6 CAPLUS COPYRIGHT 2003 ACS

388117-67-7 CAPLUS 4-Piperidinecarboxamide, 1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

388117-68-8 CAPLUS
Acetamide, N-ethyl-N-[1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

N- Et

388117-69-9 CAPLUS
3-Piperidinecarboxylic acid, 1-(6-(4-[(2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl)-4-pyrimidinyl]-, ethyl ester (9CI) (CA INDEX

ANSWER 1 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued) antiinflammatory and immunosuppressive agents) 388117-63-3 CAPLUS Morpholine, 4-[6-[4-[{2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

388117-64-4 CAPLUS
4-Piperidinol, 1-[6-[4-[(2-(1-methylethyl)phenyl]thio]-3(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9C1) (CA INDEX NAME)

388117-65-5 CAPLUS Morpholine, 2.6-dimethyl-4-[6-[4-[(2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

3-Piperidinecarboxamide, 1-{6-{4-[(2-(1-methylethyl)phenyl]thio}-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

ANSWER 1 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)

388117-70-2 CAPLUS
4-Piperidinecarboxylic acid, 1-[6-[4-[(2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]-, ethyl ester (9CI) (CA INDEX NAME)

388117-71-3 CAPLUS
1-Piperazinecarboxylic acid, 4-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]-, ethyl ester (9CI) (CA INDEX NAME)

388117-72-4 CAPLUS
1-Piperazineacetic acid, 4-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)

F<sub>3</sub>C CH<sub>2</sub>-C-OSt

RN 388117-73-5 CAPLUS
CN 4-Pyrimidinamine, N-[3-(1H-imidazol-1-yl)propyl]-6-[4-[[2-(1-methyl=thyl)phenyl]thio]-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

RN 388117-74-6 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

RN 388117-75-7 CAPLUS
CN 3-Piperidinecarboxylic acid, 1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)

RN 388117-79-1 CAPLUS
CN Pyrimidine, 4-[4-[[2-(1-methylethyl)phenyl]thio]-3(trifluoromethyl)phenyl]-6-[4-(1H-tetrazol-5-yl)-1-piperidinyl]- (9CI)
(CA INDEX NAME)

RN 388117-80-4 CAPLUS
CN 3-Piperidinemethanol, 1-[6-{4-{[2-{1-methylethyl)phenyl]thio}-3-(trifluoromethyl)phenyl}-4-pyrimidinyl}- (9CI) (CA INDEX NAME)

RN 388117-81-5 CAPLUS
CN 4-Piperidineethanol, 1-{6-{4-[{2-{1-methylethyl}phenyl}thio]-3-(trifluoromethyl)phenyl}-4-pyrimidinyl}- {9CI} (CA INDEX NAME)

RN 388117-82-6 CAPLUS
CN Acetamide, N-[1-[6-[4-[(2-(1-methylethyl)phenyl]thio]-3(trifluoromethyl)phenyl]-4-pyrimidinyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)

RN 388117-76-8 CAPLUS

Pyrimidine, 4-[4-[(2-(1-methylethyl)phenyl]thio]-3(trifluoromethyl)phenyl]-6-[4-(2-pyridinyl)-1-piperazinyl]- (9CI) (CA
INDEX NAME)

RN 388117-77-9 CAPLUS
CN 3-Piperidinecarboxamide, N,N-diethyl-1-[6-[4-[[2-[1-methylethyl]phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI)
(CA INDEX NAME)

RN 388117-78-0 CAPLUS
CN Pyrimidine, 4-(4-[(2-(1-methylethyl)phenyl]thio]-3 (trifluoromethyl)phenyl]-6-[3-(1H-tetrazol-5-yl)-1-piperidinyl]- (9CI)
 (CA INDEX NAME)

L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued

RN 388117-83-7 CAPLUS
CN Pyrimidine, 4-[(2R)-2-(methoxymethyl)-1-pyrrolidinyl]-6-[4-[(2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry

RN 388117-84-8 CAPLUS
CN 3-Pytrolidinol, 1-16-[4-{[2-(1-methylethyl)phenyl]thio]-3(trifluoromethyl)phenyl]-4-pyrimidinyl]-, (3R)- (9CI) (CA INDEX NAME)
Absolute stereochemistry.

L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)

388117-85-9 CAPLUS
Carbamic acid, [1-[6-[4-[{2-(1-methylethyl)phenyl}thio]-3[trifluoromethyl)phenyl]-4-pyrimidinyl]-3-pyrrolidinyl]-,
1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

388117-86-0 CAPLUS
4-Pyrimidinamine, N-methyl-N-(1-methylethyl)-6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

ANSWER 1 OF 6 CAPLUS COPYRIGHT 2003 ACS

L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)

RN 388117-87-1 CAPLUS CN 4-Pyrimidinamine, N-ethyl-N-methyl-6-(4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

IT 388118-57-8P 388118-58-9P
RU: RCT (Reactant): SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of aryl phenylheterocyclyl sulfides as cell adhesion-inhibiting
antinflammatory and immunosuppressive agents)
RN 388118-57-8 CAPLUS
C4 (1H)-Pyrimidinone, 6-[4-[[2-(1-methylethyl]phenyl]thio]-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

388118-58-9 CAPLUS
Pyrimidine, 4-chloro-6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2002:449662 CAPLUS
DOCUMENT NUMBER: 137:33310
Preparation of anilinopyrimidines as IKK inhibitors
Kois, Adam; MacFarlane, Karen J.; Satch, Yoshitaka;
Bhagwat, Shripad S.; Parnes, Jason S.; Palanki,
Moorthy S. S.; Erdman, Paul E.
SOURCE: Signal Pharmaceuticals, Inc., USA
PCT Int. Appl., 194 pp.
COOM: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
PAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

DOCUMENT TYPE: LANGUAGE: FAMILY ACC. NUM. COUNT: PATENT INFORMATION:

	PATENT NO.				KIND		DATE		APPLICATION NO. DATE									
					~ -					-								
	WO 2002046171			A2		20020613		WO 2001-US46403 20011205										
	WQ 2002046171			A3		20030123												
		W:	ΑE,	AG,	AL,	AM,	AT,	AU,	AZ,	BA,	BB,	BG,	BR,	BY,	BZ,	CA,	CH,	CN,
			co,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	ES,	FI,	GB,	GD,	GE.	GH,
			GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	KE.	KG,	KP,	KR.	KZ.	LC.	LK.	LR.
			LS,	LT.	LU,	LV,	MA.	MD.	MG.	MK.	MN.	MW.	MX.	MZ.	NO.	NZ.	OM.	PH.
			PL,	PT.	RO.	RU,	SD.	SE.	SG,	SI.	SK.	SL.	TJ.	TM.	TR.	TT.	TZ.	UA.
			UG,	UZ,	VN.	YU,	ZA.	ZW.	AM.	AZ.	BY.	KG.	KZ.	MD.	RU.	TJ.	TM	
		RW:	GH,	GM,	KE,	LS,	MW,	MZ,	SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW,	AT,	BE,	CH,
			CY,	DE',	DK,	ES,	FI,	FR,	GB,	GR,	IE,	IT,	LU,	MC,	NL,	PT,	SE,	TR,
			BF,	BJ,	CF,	CG,	CI,	CM,	GA,	GN,	GQ,	GW,	ML,	MR,	NE.	SN,	TD,	TG
	AU 2002020195 A5 20020618								AU 2002-20195				20011205					
PRIO	RIORITY APPLN. INFO.:						1	JS 2	000-	2518	16P	P	2000	1206				
									1	NO 2	001-	US46	403	W :	2001	1205		

OTHER SOURCE(S): MARPAT 137:33310

AB The title compds. [I; R1 = {un}substituted (hetero)aryl; R2 = H; R3 = H, alkyl; R4 = halo, OH, alkyl, alkoxy; R5, R6 = R8, (CH2)acOR9, (CH2)acO2R9, etc.; or NRSR6 = {un}substituted heterocycle; R8, R9 = H, alkyl, aryl, etc.; a = 0-4) having activity as inhibitors of IKK, particularly IKK-2, were prepd. Eg., a multi-step synthesia of I [R1 = 4-CL6H4; R2-R6 = H] having an IC50 of .ltoreq. 1 .mu.M in the IKK-2 enzyme assay, was given. Such compds. I have utility in the treatment of a wide range of conditions that are responsive to IKK inhibition. Thus, methods of treating such conditions are also disclosed, as are pharmaceutical compns. contg. one or

more compds. of the above compds. 434944-90-8P 434944-91-9P 434944-92-0P 434944-96-4P 434944-99-7P 434945-00-3P

ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)
414945-01-4P 414945-04-7P 434945-05-8P
414945-02-7P 414945-75-2P 434945-76-3P
414949-28-7P 414945-35-6P 434949-31-2P
414949-38-3P 414949-35-6P 414949-31-2P
414949-38-3P 414949-47-0P 434949-56-5P
434949-38-3P 414949-56-1P 434949-56-5P
434949-71-0P 414949-76-3P 414949-77-6P
434949-78-8P 414949-81-2P 414949-77-6P
434949-79-8P 414949-81-2P 414949-77-6P
434949-79-8P 414949-81-2P 414949-77-6P
434949-79-8P 414949-81-2P 414949-77-6P
434949-79-0P 414949-78-8P 414949-77-6P
434949-79-0P 414949-78-8P 414949-78-8P
434949-79-0P 414949-78-8P 414949-78-8P
434950-01-3P 414950-01-6P 414950-01-5P
434950-01-3P 414950-10-4P 414950-11-5P
434950-01-3P 414950-10-4P 414950-11-5P
434950-35-3P 414950-33-3P 7843950-14-2P
434950-41-5P 414950-41-5P 414950-14-5P
434950-41-4P 414950-41-5P 414950-41-2P
434950-41-4P 414950-41-5P 414950-41-5P
434950-51-3P 414950-51-3P 414950-51-3P
434950-51-3P 414950-41-5P 414950-41-5P
434950-51-3P 414950-41-5P 414950-41-5P
434950-51-3P 414950-41-5P 414950-41-5P
434950-51-3P 414950-51-3P 414950-51-3P
434950-51-3P 414950-41-5P
434950-51-3P 414950-41-5P
434950-51-3P 414950-41-5P
434950-51-3P
4349

434944-91-9 CAPLUS Benzamide, 4-[(4-(4-(4-pyridinylsulfonyl)phenyl]-2-pyrimidinyl]amino]-(9C1) (CA INDEX NAME)

ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)
Benzamide, 4-{{4-(4-(1-methyl-4-piperidinyl)sulfonyl)phenyl}-2pyrimidinyl]amino]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

СМ 1

CRN 434944-99-7 CMF C23 H25 N5 O3 S

CM

434945-01-4 CAPLUS

Benzamide, 4-[4-[4-(4-methyl-1-piperazinyl)sulfonyl]phenyl]-2pyrimidinyl]aminol- (9CI) (CA INDEX NAME)

434945-04-7 CAPLUS Benzamide, 4-[[4-[4-(phenylthio)phenyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)

434944-92-0 CAPLUS Benzamide, 4-[(4-[4-(2-pyridinylaulfonyl)phenyl]-2-pyrimidinyl)amino]-(9CI) (CA INDEX NAME)

434944-96-4 CAPLUS Benzamide, 4-[4-(3-pyridinylsulfonyl)phenyl]-2-pyrimidinyl]amino]-(9CI) (CA INDEX NAME)

434944-99-7 CAPLUS Benzamide, 4-[(1-methyl-4-piperidinyl)sulfonyl]phenyl]-2-pyrimidinyl]smino]- (9CI) (CA INDEX NAME)

434945-00-3 CAPLUS

ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS

434945-05-8 CAPLUS Benzamide, 4-[4-[4-(phenylsulfonyl)phenyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

434945-27-4 CAPLUS
Morpholine, 4-{4-[4-[4-(phenylsulfonyl)phenyl]-2-pyrimidinyl]amino}benzoyl}- (9CI) (CA INDEX NAME)

434945-75-2 CAPLUS
Piperazine, 1-acetyl-4-[4-[4-[4-[4-pyridinylsulfonyl)phenyl]-2pyrimidinyllamino|benzoyl)- (9CI) (CA INDEX NAME)

434945-76-3 CAPLUS

CN Piperazine.

1-(2-furanylcarbonyl)-4-[4-[[4-[4-(4-pyridinylgulfonyl)phenyl]-2-pyrimidinyl]amino|benzoyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)

RN 434949-28-7 CAPLUS
CN Piperazine, 1-(2-furanylcarbonyl)-4-[4-[4-[4-(4-morpholinylgulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)

RN 434949-29-8 CAPLUS
CN Piperazine, 1-acetyl-4-[4-[4-[4-(4-morpholinylsulfonyl)phenyl]-2pyrimidinyl]amino|benzoyl]- (9CI) (CA INDEX NAME)

RN 434949-31-2 CAPLUS
CN Piperazine, 1-[4-[4-[4-(4-morpholinylsulfonyl)phenyl]-2pyrimidinyl|amino|benzoyl|- (9CI) (CA INDEX NAME)

RN 434949-33-4 CAPLUS
CN 1-Piperazineacetamide, N-(1-methylethyl)-4-[4-[4-[4-(4-morpholinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)

PAGE 2-A

PAGE 1-A

RN 434949-40-3 CAPLUS
CN 4-Piperidinol, 1-[4-[4-[4-morpholinylsulfonyl)phenyl]-2pyrimidinyl]aminolbenzoyl]- (9CI) (CA INDEX NAME)

RN 43494-42-5 CAPLUS
CN Piperidine, 1-[4-[4-(4-morpholinylsulfonyl)phenyl]-2pyrinidinyllamino|benzoyl]-4-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)

Habte

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued) NAME)

$$\bigcap_{N} \bigcap_{N} \bigcap_{N} \bigcap_{N+1} \bigcap_{N+2} \bigcap_$$

RN 434949-35-6 CAPLUS
CN Piperazine, 3-methyl-1-[4-[4-[4-(4-morpholinylsulfonyl)phenyl]-2pyrimidinyl]amino]benzoyl)-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 434949-36-7 CAPLUS
CN 1-Piperazinepropanamine, N,N-dimethyl-4-[4-[4-[4-(4-morpholinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX

RN 434949-38-9 CAPLUS
CN Piperazine, 1-[4-[4-(4-morpholinylaulfonyl)phenyl]-2pyrimidinylamino|benzoyl]-4-[2-oxo-2-(1-pyrrolidinyl)ethyl]- (9CI) (CA
INDEX NAME)

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)

PAGE 2-A

RN 434949-44-7 CAPLUS
CN Piperazine, 1-(cyclopropylcarbonyl)-4-[4-[4-(4morpholinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA
INDEX

4/8/2003

NAME)

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued) NAME)

N S NH NH C NN C Bu-t

RN 434949-50-5 CAPLUS
CN Piperazine, 1-[4-[4-(4-morpholinylsulfonyl)phenyl]-2pyrimidinyl}amino|benzoyl]-4-(1-oxopropyl)- (9CI) (CA INDEX NAME)

NH NH C-EI

RN 434949-53-8 CAPLUS
CN Piperazine, 1-[4-[(4-[4-(4-morpholinylsulfonyl)phenyl]-2pyrimidinyl]amino|benzoyl]-4-(1-oxobutyl)- (9C1) (CA INDEX NAME)

NH NH C-Pr-

RN 434949-56-1 CAPLUS
CN Piperazine, 1-([3,5-dimethyl-4-isoxazolyl)carbonyl]-4-[4-[4-(4-morpholinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (GA INDEX
NAME)

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)

I NH NH NH

RN 434949-71-0 CAPLUS
CN Piperazine, 1-acetyl-4-[4-[4-[4-[4-hydroxy-1-piperidinyl]sulfonyl]phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)

HO NH C N AC

RN 434949-74-3 CAPLUS
CN Piperazine, 1-[4-[4-{4-{(4-hydroxy-1-piperidiny1)sulfony1]pheny1}-2-pyrimidiny1]amino]benzoy1]- (9CI) (CA INDEX NAME)

NH NH NH

RN 43494-77-6 CAPLUS
CN Piperidine, 1-[4-[4-[4-(4-hydroxy-1-piperidinyl)aulfonyl]phenyl]-2pyrimidinyllamino|benzyl]-4-(1-pyrrolidinyl)- (9Cl) (CA INDEX NAME)

HO NH NH NH NH

RN 434949-79-8 CAPLUS
CN Piperazine.
1-acetyl-4-(4-[4-[4-[4-(4-methyl-1-piperazinyl)sulfonyl]phenyl]2-pyrimidinyl]amino|benzoyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)

PAGE 1-A

PAGE 2-A

RN 434949-68-5 CAPLUS
CN Piperazine, 1-(2-furanylcarbonyl)-4-{4-{4-{4-{4-hydroxy-1-piperidinyl}aulfonyl}phenyl}-2-pyrimidinyl}amino|benzoyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)

RN 434949-81-2 CAPLUS
CN Piperazine, 1-acety1-4-[{4-[2-[(4-[4-acety1-1-piperazinyl)carbonyl]phenyl]amino]-4-pyrimidinyl]phenyl]sulfonyl]- (9CI)
(CA INDEX NAME)

AC N NH NH AC

RN 434949-83-4 CAPLUS
CN 4-Piperidinecarboxamide, 1-[4-[2-[4-[(4-acetyl-1-piperazinyl)carbonyl]phenyl]amino]-4-pyrimidinyl]phenyl]sulfonyl]-N,N-dimethyl- (9C1) (CA INDEX NAME)

Me<sub>2</sub>N-

RN 434949-85-6 CAPLUS
CN Piperazine, 1-acety1-4-[4-[[4-[4-(1-piperidinylsulfonyl)phenyl]-2-pyrimidinyllamino)benzoyll- (9Cl (CA INDEX NAME)

NNH C N AC

RN 434949-87-8 CAPLUS
CN Piperazine, 1-acetyl-4-[4-[4-[4-(1-pyrrolidinylaulfonyl)phenyl]-2-pyrimidinyl]amino|benzoyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)

434949-91-4 CAPLUS
Piperazine, 1-acetyl-4-{4-[{4-[4-[4-[4-(1-pyrrolidinyl)-1-piperidinyl]sulfonyl]phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)

434949-94-7 CAPLUS
Piperazine, 1-acety1-4-[4-[4-[4-(hexahydro-1H-azepin-1ylisulfonyl]phenyl]-2-pyrimidinyl]amino|benzoyl]- (9CI) (CA INDEX NAME)

ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS

434949-99-2 CAPLUS
Piperazine, 1-acety1-4-[4-[4-[4-(1-piperazinylsulfonyl)phenyl]-2pyrimidinyllaminojbenzoyl]- (9CI) (CA INDEX NAME)

434950-03-5 CAPLUS
Piperazine, 1-[4-[4-(4-(1-piperidinylsulfonyl)phenyl]-2pyrimidinyl]amino|benzoyl)- (9Cl) (CA INDEX NAME)

434950-04-6 CAPLUS
Piperazine, 1-[4-[4-[4-[4-[4-pyrrolidinylsulfonyl)phenyl]-2pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)

Habte

RN 434950-05-7 CAPLUS
CN Piperazine, 3,5-dimethyl-1-[4-[4-(4-(1-piperidinylsulfonyl)phenyl]-2-

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)

RN 434949-95-8 CAPLUS CN Piperazine, 1-acetyl-4-[4-[4-[4-[4-remethyl-1-piperidinyl]gulfonyl]phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)

434949-96-9 CAPLUS
Piperazine,
retyl-4-[4-[4-[4-(4-methyl-1-piperidinyl)aulfonyl]phenyl]2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)

RN 434949-97-0 CAPLUS CN Piperazine, 1-acetyl-4[-[(4-[4-[(3-methyl-1-piperidinyl)sulfonyl]phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)

ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued) pyrimidinyl}amino}benzoyl]-, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

434950-07-9 CAPLUS Piperazine, -cthoxyethyll-4-[4-[4-[4-(1-piperidinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)

434950-08-0 CAPLUS
Piperazine, 3.5-dimethyl-1-[4-[4-(1-pyrrolidinylsulfonyl)phenyl]-2pyrimidinyl]amino]benzoyl]-, (3R,SS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)

RN 434950-09-1 CAPLUS
CN Piperazine,
1-(2-ethoxyethyl)-4-[4-[4-[4-(1-pyrrolidinylsulfonyl)phenyl]2-pyrimidinyl]amino]benzoyl]- (9Cl) (CA INDEX NAME)

434950-10-4 CAPLUS
1-Piperazinepropanamine, N,N-dimethyl-4-{4-{[4-{4-{1-pyrrolidinylaulfonyl)phenyl}-2-pyrimidinyl}amino|benzoyl]- (9CI) (CA INDEX NAME)

ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)

434950-13-7 CAPLUS
Piperazine, 3,5-dimethyl-1-[4-[[4-[4-(4-morpholinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]-, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

RN 434950-14-8 CAPLUS
CN Piperazine.
1-(2-ethoxyethyl)-4-(4-[(4-[4-(4-morpholinylsulfonyl)phenyl]-2pyrimidinyl]amino]benzoyl)- (9CI) (CA INDEX NAME)

, CH2 — CH2 — OEt

RN 434950-15-9 CAPLUS
CN 1-Fiperazineethanamine, N,N-dimethyl-4-[4-[4-[4-(4-morpholinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX

RN 434950-33-1 CAPLUS
CN 1-Piperazinepropanamine,
N,N-dimethyl-4-{4-{[tetrahydro-2H-pyran-4-yl)aulfonyl]phenyl}-2-pyrimidinyl}amino|benzoyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)

NAME)

ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)

434950-34-2 CAPLUS
4-Piperidinol, 1-{4-({4-[4-(4-pyridinylsulfonyl)phenyl}-2-pyrimidinyl]amino|benzoyl]- (9CI) (CA INDEX NAME)

434950-35-3 CAPLUS
Piperazine, 1-(3,5-dimethyl-4-isoxazolyl)carbonyl]-4-(4-(4-(4-pyridinylsulfonyl)phenyl)-2-pyrimidinyl]amino]benzoyl)- (9CI) (CA INDEX NAME)

PAGE 1-A

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)

PAGE 2-A

434950-36-4 CAPLUS
Piperazine, 1-(2-furanylcarbonyl)-4-[4-[[4-[4-[(tetrahydro-2H-pyran-4-y1)sulfonyl]phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)

RN 434950-37-5 CAPLUS
CN 1-Piperazineacetamide,
N-(1-methylethyl)-4-{4-[(4-[(tetrahydro-2H-pyran4-yl)sulfonyl]phenyl]-2-pyrimidinyl]amino]benzoyl)- (9CI) (CA INDEX NAME)

434950-38-6 CAPLUS
Piperazine, 1-[4-[[4-[(tetrahydro-2H-pyran-4-yl)sulfonyl]phenyl]-2pyrimidinyl]amino]benzoyl]- (9Cl) (CA INDEX NAME)

ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)

PAGE 1-A

PAGE 2-A

434950-43-3 CAPLUS
Piperazine, 1-acety1-4-[4-[4-(4-(tetrahydro-2H-pyran-4yl)sulfonyl]phanyl1-2-pyrimidinyl]amino|benzoyl]- (9C1) (CA INDEX NAME)

434950-44-4 CAPLUS
Piperazine, 1-[4-[[4-[4-(4-pyridinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)

Habte

ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued) 434950-39-7 CAPLUS Piperazine, 3-methyl-1-[4-[4-[4-[(tetrahydro-2H-pyran-4-yl) aulfonyl]phenyl]-2-pyrimidinyl]amino]benzoyl]-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

434950-40-0 CAPLUS
Piperidine, 4-(1-pyrrolidinyl)-1-[4-[[4-[4-[(tetrahydro-2H-pyran-4-yl)sulfonyl]phenyl]-2-pyrimidinyl]amino)benzoyl]- (9CI) (CA INDEX NAME)

434950-41-1 CAPLUS
4-Piperidinol, 1-[4-[[4-[4-[(tetrahydro-2H-pyran-4-yl)sulfonyl]phenyl]-2-pyrimidinyl]aminojbenzoyl]- (9CI) (CA INDEX NAME)

434950-42-2 CAPLUS
Piperazine, 1-{(3,5-dimethyl-4-isoxazolyl)carbonyl}-4-{4-[{4-{4-((tetrahydro-2H-pyran-4-yl)sulfonyl}phenyl}-2-pyrimidinyl}amino}benzoyl}(9CI) (CA INDEX NAME)

ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)

434950-45-5 CAPLUS
Piperazine, 1-(2-ethoxyethyl)-4-[4-[[4-[4-(phenylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)

434950-46-6 CAPLUS
Piperazine, 1-[4-[4-[4-(phenylsulfonyl)phenyl]-2pyrimidinyl]smino]benzoyl)-4-[(tetrahydro-2-furanyl)methyl]- (9CI) (CA
INDEX NAME)

434950-47-7 CAPLUS
Piperazine, 1-acetyl-4-[4-[4-[4-(phenylsulfonyl)phenyl]-2pyrimidinyl]amino]benzoyl)- (9CI) (CA INDEX NAME)

434950-48-8 CAPLUS
Piperazine, 1-(2-furanylcarbonyl)-4-[4-[(4-[4-(phenylsulfonyl)phenyl]-2-pyrimidinyl]amino|benzoyl]- (9CI) (CA INDEX NAME)

ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)

434950-49-9 CAPLUS
Piperazine, 1-methyl-4-[4-[4-[4-[4-(phenylsulfonyl)phenyl]-2-pyrimidinyl]amino|benzoyl)- (9CI) (CA INDEX NAME)

434950-50-2 CAPLUS
Piperazine, 1-[4-[[4-[4-(phenylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]-, dihydrochloride (9CI) (CA INDEX NAME)

●2 HC1

RN 434950-51-3 CAPLUS
CN 1-Piperazinepropanamine,
N,N-dimethyl 4-{4-{4-{phenylsulfonyl}phenyl}2-pyrimidinyl]amino]benzoyl}- (9CI) (CA INDEX NAME)

ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)
Benzoic acid, 4-[(4-(4-((tetrahydro-2H-pyran-4-yl)sulfonyl]phenyl]-2pyrimidinyl]aminol- (9CI) (CA INDEX NAME)

ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)

434950-52-4 CAPLUS Benzamide, N. (4-hydroxycyclohexyl)-4-[{4-{4-(phenylsulfonyl)phenyl}-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

434950-53-5 CAPLUS
Benzamide, N, N-dimethyl-4-[(4-[4-(phenylsulfonyl)phenyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

434950-65-99 434950-68-29
RL: RCT (Reactant); SPM (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of anilinopyrimidines as IKK inhibitors)
434950-65-9 CAPUUS IТ

Benzoic acid,

4-{(4-[4-(4-morpholinylsulfonyl)phenyl}-2-pyrimidinyl)amino}-(9CI) (CA INDEX NAME)

434950-68-2 CAPLUS

L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2002:449661 CAPLUS
DOCUMENT NUMBER: 137:33309
ITILE: 137:33309
INVENTOR(S): Kois, Adam, MacFarlane, Karen J.; Satoh, Yoshitaka; Bhagwat, Shripad S.: Parnes, Jason S.; Palanki, Moorthy S. S.; Erdman, Paul E.
SOURCE: Signal Pharmaceuticals, Inc., USA
PCT Int. Appl., 199 pp.
CODEM: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: PALENT
FAMILY ACC. NUM. COUNT: 1

DOCUMENT TYPE: LANGUAGE: FAMILY ACC. NUM. COUNT: PATENT INFORMATION:

KIND DATE APPLICATION NO. DATE PATENT NO. KIND DATE WO 2002045170 A2 20020613 WO 2001-US46402 20011205
N: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BB, BR, BY, BY, BZ, CA, CH,
CG, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,
LS, LT, LU, LV, NA, MD, MG, MK, NN, MM, MX, MZ, NO, NZ, OM,
PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, TJ, TM, TR, TT, TZ,
UG, UZ, VN, YU, ZA, ZM, ZM, AM, AZ, BY, KG, KZ, LC, LM,
RW, GH, GM, KE, LS, MM, MZ, SD, SL, SZ, TZ, UG, ZM, ZM, ZM, ZM, ZM, ZM, ZM, ZM, AM, AZ, BP, KG, KZ, MD, RU, TJ,
RW, GH, GM, KE, LS, MM, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE,
CY, DB, DK, ES, FI, FR, GB, GR, IE, LT, LU, MC, NL, PT, SE,
AU 2002027214 A5 20020618 AU 2002-27214 20011205
OTHER SOURCE(S):

MARPAT 137:33309

AB The title compds. [I; R1 = (un)substituted (hetero)aryl; R2 = H; R3 = H, alkyl; R4 = halo, OH, alkyl, alkoxy; R5, R6 = R8, (CH2)aCOR9, (CH2)aCOR9, etc.; or NR5R6 = (un)substituted heterocycle; R8, R9 = H, alkyl, aryl, etc.; a = 0-4) having activity as inhibitors of the JNK pathway, were prepd. E.g., a multi-step synthesis of I [R1 = 4-ClC6H4; R2-R6 = H) having an ICSO of .ltoreq. 10 .mm.M in the JNK2 assey, was given. Such compds. I have utility in the treatment of a wide range of conditions that

are responsive to inhibition of the JNK pathway. Thus, methods of treating such conditions are also disclosed, as are pharmaceutical

ns. contg. one or more compds. of the above compds. 434944-90-8P 434944-91-9P 434944-92-0P 434944-96-4P 434944-99-7P 434945-00-3P

ANSMER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS 434945-01-4P 414945-04-4P 434945-05-8P 434945-01-4P 414945-05-8P 434945-05-8P 434945-31-2P 434945-31-3P 43495-31-3P 43 (Continued) RE: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. of anilinopyrimidines as JNK pathway inhibitors) 434944-90-8 CAPLUS Benzamide Benzamide [4-[(4-chlorophenyl)sulfonyl]phenyl]-2-pyrimidinyl]amino]-(9CI) (CA INDEX NAME)

434944-91-9 CAPLUS Benzamide, 4-[4-[4-eyridinylsulfonyl)phenyl]-2-pyrimidinyl]amino]-(9CI) (CA INDEX NAME)

ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)
Benzamide, 4-[(4-(4-[(1-methyl-4-piperidinyl)sulfonyl)phenyl]-2pyrimidinyl]amino]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

434945-01-4 CAPLUS Benzamide, 4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

434945-04-7 CAPLUS Benzamide, 4-[(4-[4-(phenylthio)phenyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)

434944-92-0 CAPLUS Benzamide, 4-[(4-14-(2-pyridinylsulfonyl)phenyl]-2-pyrimidinyl]amino]-(9CI) (CA INDEX NAME)

434944-96-4 CAPLUS Benzamide, 4-[(4-(3-pyridinylaulfonyl)phenyl]-2-pyrimidinyl]amino]-(9CI) (CA INDEX NAME)

434944-99-7 CAPLUS

Benzamide, 4-[(4-4-[(1-methyl-4-piperidinyl)sulfonyl]phenyl]-2pyrimidinyl]aminol- (9CI) (CA INDEX NAME)

434945-00-3 CAPLUS

ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)

434945-05-8 CAPLUS Benzamide, 4-[[4-[4-(phenylsulfonyl)phenyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

434945-27-4 CAPLUS
Morpholine, 4-[4-[4-[4-(phenylsulfonyl)phenyl]-2pyrimidinyl]amino]benzoyl]- (CA INDEX NAME)

434945-75-2 CAPLUS
Piperazine, 1-acety1-4-[4-[4-[4-[4-(4-pyridinylsulfonyl)phenyl]-2-pyrimidinyllamino]benzoyll- (9CI) (CA INDEX NAME)

RN 434945-76-3 CAPLUS
CN Piperazine,
1-(2-furanylcazbonyl)-4-[4-[4-[4-(4-pyridinylaulfonyl)phenyl]2-pyrimidinyl]amino|benzoyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)

RN 434949-28-7 CAPLUS
CN Piperazine, 1-(2-furanylcarbonyl)-4-[4-[4-[4-(4morpholinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA
INDEX
NAME)

RN 434949-29-8 CAPLUS
CN Piperazine, 1-acetyl-4-[4-[4-[4-(4-morpholinylsulfonyl)phenyl]-2pyrimidinyl]aminojbenzoyl]- (9C1) (CA INDEX NAME)

RN 434949-31-2 CAPLUS
CN Piperazine, 1-[4-[4-[4-(4-morpholinylsulfonyl)phenyl]-2pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)

RN 434949-33-4 CAPLUS
CN 1-Piperazineacetamide, N-[1-methylethyl]-4-[4-[4-[4-[4-(4-morpholinylsulfonyl]phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA

L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)

PAGE 2-A

PAGE 1-A

RN 434949-40-3 CAPLUS
CN 4-Piperidinol, 1-[4-{[4-[4-(4-morpholinylsulfonyl)phenyl]-2-pyrimidinyl]amino|benzoyl}- (9CI) (CA INDEX NAME)

Habte

RN 434949-42-5 CAPLUS
CN Piperidine, 1-[4-[4-[4-(4-morpholinylaulfonyl)phenyl]-2pyrimidinyl]amino]benzoyl]-4-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued) NAME)

RN 434949-35-6 CAPLUS
CN Piperazine, 3-methyl-1-[4-[(4-(4-morpholinylsulfonyl)phenyl]-2pyrimidinyllamino|benzoyl]-, (3R)- (9Cl) (CA INDEX NAME)

Absolute stereochemistry.

RN 434949-38-9 CAPLUS
CN Piperazine, 1-[4-[4-[4-(4-morpholinylsulfonyl)phenyl]-2pyrimidinyl]amino]benzoyl]-4-[2-oxo-2-(1-pyrrolidinyl)ethyl]- (9CI) (CA
INDEX NAME)

L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)

PAGE 2-A

RN 434949-47-0 CAPLUS
CN Piperazine, 1-(2,2-dimethyl-1-oxopropyl)-4-[4-([4-[4-(4-morpholinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX

ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued) NAME)

434949-50-5 CAPLUS
Piperazine, 1-(4-(14-(4-morpholinylsulfonyl)phenyl]-2pyrimidinyl]amino|benzoyl]-4-(1-oxopropyl)- (9CI) (CA INDEX NAME)

434949-53-8 CAPLUS
Piperazine, 1-[4-[4-(4-morpholinylsulfonyl)phenyl]-2pyrimidinyl]amino]benzoyl]-4-(1-oxobutyl)- (9CI) (CA INDEX NAME)

434949-56-1 CAPLUS
Piperazine, 1-[(3,5-dimethyl-4-isoxazolyl)carbonyl]-4-[4-[4-[4-(4-morpholinylsulfonyl)phenyl]-2-pyrimidinyl}amino|benzoyl|- (9Cl) (CA

NAME)

L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)

PAGE 1-A

PAGE 2-A

434949-68-5 CAPLUS
Piperazine, 1-(2-furanylcarbonyl)-4-[4-[4-[4-(4-hydroxy-1-piperidinyl]sulfonyl]phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)

ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS

434949-71-0 CAPLUS
Piperazine, 1-acety1-4-[4-[4-[4-[4-hydroxy-1piperidinyl)sulfonyl]phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA
RUBEX NAME)

434949-74-3 CAPLUS
Piperazine, 1-[4-[4-[4-[4-hydroxy-1-piperidinyl]sulfonyl]phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)

434949-77-6 CAPLUS
Piperidine, 1-[4-{[4-{(4-(4-hydroxy-1-piperidiny1)sulfony1]pheny1]-2-pyrimidiny1]aminojbenzoy1]-4-(1-pyrrolidiny1)- (9C1) (CA INDEX NAME)

434949-79-8 CAPLUS
Piperazine,
tectyl-4-{4-[4-[4-[4-[4-methyl-1-piperazinyl]sulfonyl]phenyl]2-pyrimidinyl]amino|benzoyl]- (9CI) (CA INDEX NAME)

ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS

434949-81-2 CAPLUS
Piperazine, 1-acetyl-4-[[4-[2-[[4-[(4-acetyl-1-piperaziny])|carbonyl]phenyl]amino]-4-pyrimidinyl]phenyl]aulfonyl]- (9CI)
(CA INDEX NAME)

434949-83-4 CAPLUS
4-Piperidinecarboxamide, 1-[[4-[2-[[4-[(4-acetyl-1-piperazinyl)carbonyl]phenyl]amino]-4-pyrimidinyl]phenyl]sulfonyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)

434949-85-6 CAPLUS
Piperazine, 1-acety1-4-[4-[4-(4-(1-piperidinylsulfonyl)phenyl]-2pyrimidinyl]aminolbenzoyll- (SCI) (CA INDEX NAME)

434949-87-8 CAPLUS
Piperazine, 1-acetyl-4-[4-[4-[4-[4-pyrrolidinylsulfonyl)phenyl]-2-pyrindinyllamino|benzoyl]- (9CI) (CA INDEX NAME)

ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)

434949-91-4 CAPLUS
Piperazine, 1-acetyl-4-[4-[4-[4-[4-(1-pyrrolidinyl)-1-piperidinyl]sulfonyl]phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CAINDEX NAME)

434949-94-7 CAPLUS
Piperazine, 1-acetyl-4-[4-[4-[4-(hexahydro-1H-azepin-1-yl)sulfonyl]phenyl]-2-pyrimidinyl)aminolbenzoyl]- (9CI) (CA INDEX NAME)

ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)

434949-99-2 CAPLUS
Piperazine, 1-acetyl-4-[4-[4-[4-[4-[4-piperazinylsulfonyl)phenyl]-2-pyrimidinyl]amino|benzoyl]- (9Cl) (CA INDEX NAME)

434950-03-5 CAPLUS
Piperazine, 1-[4-[4-(1-piperidinylsulfonyl)phenyl]-2-pyrimidinyl]amino|benzoyl]- (9CI) (CA INDEX NAME)

434950-04-6 CAPLUS
Piperazine, 1-[4-[4-[4-(1-pyrrolidinylsulfonyl)phenyl]-2-pyrimidinyl]amino|benzoyl]- (9CI) (CA INDEX NAME)

RN 434950-05-7 CAPLUS
CN Piperazine, 3,5-dimethyl-1-[4-[4-[4-(1-piperidinylsulfonyl)phenyl]-2-Habte

L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)

RN 434949-95-8 CAPLUS CN Piperazine, 1-acetyl-4-[4-[4-[4-[4-(2-methyl-1-piperidinyl)sulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)

434949-96-9 CAPLUS
Piperazine,
cetyl-a-{4-[4-[4-{4-(4-methyl-1-piperidinyl)sulfonyl}phenyl]2-pyrimidinyl]amino|benzoyl}- (9CI) (CA INDEX NAME)

RN 434949-97-0 CAPLUS CN Piperazine, 1-acetyl-4-[4-[4-[4-[(3-methyl-1-piperidinyl)aulfonyl]phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)

434949-98-1 CAPLUS
Piperazine, 1-acety1-4-[4-[4-[4-[(3-hydroxy-1-piperidinyl)sulfonyl]phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA
RUDEX NAME)

ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued) pyrimidinyl]amino]benzoyl]-, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

NAME)

434950-07-9 CAPLUS Piperazine, -ethoxyethyl)-4-[4-[4-[4-(1-piperidinylaulfonyl)phenyl]-2-pyrimidinyl)amino)benzoyl)- (9CI) (CA INDEX NAME)

434950-08-0 CAPLUS
Piperazine, 3.5-dimethyl-1-(4-{[4-(4-(1-pyrrolidinylsulfonyl)phenyl]-2pyrimidinyl|smino|benzoyl]-, (3R.5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)

RN 434950-09-1 CAPLUS
CN Piperazine,
1-(2-ethoxyethyl)-4-[4-[4-[4-(1-pyrrolidinylsulfonyl)phenyl]2-pyrimidinyl]amino]benzoyl]- (9Cl) (CA INDEX NAME)

434950-10-4 CAPLUS
1-Piperazinepropanamine, N,N-dimethyl-4-[4-[4-[4-(1-pyrrolidinylsulfonyl)phenyl]-2-pyrimidinyl]amino|benzoyl]- (9CI) (CA INDEX NAME)

ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)

434950-13-7 CAPLUS
Piperazine, 3,5-dimethyl-1-[4-[[4-[4-(4-morpholinylaulfonyl)phenyl]-2-pyrimidinyl]amino|benzoyl]-, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

RN 434950-14-8 CAPLUS
CN Piperazine.
1-(2-ethoxyethyl)-4-[4-[4-[4-(4-morpholinylsulfonyl)phenyl]-2pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)

RN 434950-33-1 CAPLUS
CN 1-Piperazinepropanamine,
N,N-dimethyl-4-[4-[(letrahydro-2H-pyran-4yl)sulfonyl)phanyl)-2-pyrimidinyl)amino|benzoyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)

RN 434950-12-6 CAPLUS
CN 1-Piperazineethanamine, N,N-dimethyl-4-[4-[4-(4-(1-piperidinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CAINDEX NAME)

ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS

434950-34-2 CAPLUS
4-Piperidinol, 1-[4-[4-(4-(4-pyridinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl)- (9CI) (CA INDEX NAME)

434950-35-3 CAPLUS
Piperazine, 1-[(3,5-dimethyl-4-isoxazolyl)carbonyl]-4-[4-[4-(4-pyridinylsulfonyl)phenyl]-2-pyrimidinylamino]benzoyl]- (9CI) (CA INDEX NAME)

PAGE 1-A

L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)

PAGE 2-A

434950-36-4 CAPLUS
Piperazine, 1-{2-furanylcarbonyl}-4-[4-[[4-[(tetrahydro-2H-pyran-4-yl]aulfonyl]phenyl}-2-pyrimidinyl]amino|benzoyl]- (9CI) (CA INDEX NAME)

RN 434950-37-5 CAPLUS
CN 1-Piperazineacetamide,
N-(1-methylechyl)-4-{4-[4-[4-[(tetrahydro-2H-pyran4-yl)sulfonyl]phenyl}-2-pyrimidinyl]amino|benzoyl]- (9CI) (CA INDEX

434950-38-6 CAPLUS
Piperazine, 1-[4-[(4-[4-((tetrahydro-2H-pyran-4-yl)sulfonyl)phenyl]-2pyrandinyllamino|benzoyl]- (9CI) (CA INDEX NAME)

ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS

PAGE 1-A

PAGE 2-A

434950-43-3 CAPLUS
Piperazine, 1-acety1-4-[4-[4-[4-((tetrahydro-2H-pyran-4yl)sulfonyl]phenyl]-2-pyrimidinyl]sminolbenzoyl]- [9C1] (CA INDEX NAME)

434950-44-4 CAPLUS
Piperazine, 1-[4-[[4-[4-(4-pyridinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)

Habte

ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)
434950-39-7 CAPLUS
Piperazine, 3-methyl-1-{4-{4-{4-{tetrahydro-2H-pyran-4-y1}sulfonyl}phenyl}-2-pyrimidinyl}amino|benzoyl}-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

434950-40-0 CAPLUS
Piperidine, 4-(1-pyrrolidinyl)-1-[4-[[4-[4-[(tetrahydro-2H-pyran-4yl)sulfonyl]phenyl]-2-pyrimidinyl]amino|benzoyl]- (9C1) (CA INDEX NAME)

434950-41-1 CAPLUS
4-Piperidinol, 1-[4-[[4-[4-[(tetrahydro-2H-pyran-4-yl)sulfonyl]phenyl]-2-pyrimdinyl]aminojbenzoyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)

434950-45-5 CAPLUS
Piperazine, 1-(2-ethoxyethyl)-4-[4-[[4-[4-(phenylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)

434950-46-6 CAPLUS
Piperazine, 1-[4-[4-(4-(phenylsulfonyl)phenyl]-2pyrimidinyl]amino]benzoyl]-4-[(tetrahydro-2-furanyl)methyl]- (9CI) (CA
INDEX NAME)

434950-47-7 CAPLUS
Piperazine, 1-acetyl-4-[4-[4-(4-(phenylsulfonyl)phenyl]-2pyrimidinyljaminojbenzoyl]- (9CI) (CA INDEX NAME)

434950-48-8 CAPLUS Piperazine, 1-(2-furanylcarbonyl)-4-(4-[(4-(4-(phenylsulfonyl)phenyl)-2-pyrimidinyllamino|benzoyll- (9CI) (CA INDEX NAME)

ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)

434950-49-9 CAPLUS Piperazine, 1-methyl-4-[4-[[4-[4-(phenylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)

434950-50-2 CAPLUS
Piperazine, 1-[4-[4-(phenylaulfonyl)phenyl]-2pyrimidinyl]amino|benzoyl]-, dihydrochloride (9CI) (CA INDEX NAME)

## ●2 HCl

RN 434950-51-3 CAPLUS
CN 1-Piperazinepropanamine,
N,N-dimethyl-4-[4-[4-[4-(henylsulfonyl)phenyl]2-pyrimidinyl]amino]benzoyl]- (9C1) (CA INDEX NAME)

ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)
Benzoic acid, 4-[[4-[4-[(tetrahydro-2H-pyran-4-y1)sulfony1]pheny1]-2pyrimidiny1]amino]- (9CI) (CA INDEX NAME)

ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)

RN CN

434950-52-4 CAPLUS
Benzamide, N. (4-hydroxycyclohexyl)-4-[[4-[4-(phenylsulfonyl)phenyl]-2-pyrimidnyl]aminoj- (9CI) (CA INDEX NAME)

434950-53-5 CAPLUS
Benzamide, N,N-dimethyl-4-[(4-[4-(phenylsulfonyl)phenyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

$$\mathsf{Ph}^{-1} = \mathsf{NH}^{-1} = \mathsf{NH}^{-1} = \mathsf{NH}^{-1}$$

IT 434950-65-9P 434950-68-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of anilinopyrimidines as JNK pathway inhibitors)
RN 43495-65-9 CAPULS
Benzoic acid,
4-[(4-[4-(A-morpholinylaulfonyl)phenyl]-2-pyrimidinyl]amino](9CI) (CA INDEX NAME)

HOoc

434950-68-2 CAPLUS

L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS ACCESSION NUMBER: 2002:31429 CAPLUS 2002:31429 CAPLUS 136:102394

DOCUMENT NUMBER:

136:102394
Aryl phenylheterocyclyl sulfide derivatives and their use as cell adhesion-inhibiting anti-inflammatory and immune-suppressive agents
Mang, Gary T.; Wang, Sheldon; Gentles, Robert
Abbott Lab., USA
PCT Int. Appl., 135 pp.
CODEN: PIXXD2
Patent
English
1 TITLE:

INVENTOR(S):

PATENT ASSIGNEE(S): SOURCE:

DOCUMENT TYPE: LANGUAGE: FAMILY ACC. NUM. COUNT: PATENT INFORMATION:

Title compds. were prepd. for treating inflammatory and immune diseases, such as arthritis, asthma, reperfusion injury, inflammatory bowel disease etc. The products had 1050 <30 mM for inhibition of ICAM-1 binding to LFA-1. 2-Me2CHG6H4SHwas etherified with 4,3-F(93)CGH3COME, followed by bromination, and reaction with 1-carbamoylpiperidine to give the sulfide I.

I.

1. 388118-57-8P 388118-58-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of arryl phenylheterocyclyl sulfides as cell adhesion-inhibiting
antiinflemmatory and immunosuppressive agents)
RN 388118-57-8 CAPLUS

ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued) 4 (1H)-Pyrimidinone, 6-[4-[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

388118-58-9 CAPLUS
Pyrimidine, 4-chloro-6-[4-[{2-(1-methylethyl)phenyl]thio]-3(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

388117-63-3P 388117-64-4P 388117-65-5P 388117-66-6P 388117-67-7P 388117-68-3P 388117-68-3P 388117-76-3P 388117-78-3P 388117-78-3P 388117-71-3P 388117-81-5P 38811

38817-87-19
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of aryl phenylheterocyclyl sulfides as cell adhesion-inhibiting
antiinflammatory and immunosuppressive agents)
RN 388117-63-3 CAPLUS
CN Morpholine, 4-16-[4-1[2-(1-methylethyl]phenyl]thio]-3(trifluoromethyl)phenyl]-4-pyrimidinyl]- (SCI) (CA INDEX NAME)

388117-64-4 CAPLUS 4-Piperidinol, 1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-

ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)

388117-68-8 CAPLUS Acctamide, N-ethyl-N-[1-[6-[4-[{2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]-3-pyrrolidinyl]- (9C1) (CA INDEX

388117-69-9 cAPLUS
3-Piperidinecarboxylic acid, 1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]-, ethyl ester (9CI) (CA INDEX

388117-70-2 CAPLUS
4-Piperidinecarboxylic acid, 1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]-, ethyl eater [9CI) (CA INDEX NAME)

ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued) (trifluoromethyl)phenyl)-4-pyrimidinyl)- (9CI) (CA INDEX NAME)

388117-65-5 CAPLUS Morpholine, 2,6-dimethyl-4-(6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl)- (9CI) (CA INDEX NAME)

388117-66-6 CAPLUS
3-Piperidinecarboxamide, 1-{6-{4-{{2-(1-methylethyl)phenyl}thio}-3-(trifluoromethyl)phenyl}-4-pyrimidinyl}- (9CI) (CA INDEX NAME)

388117-67-7 CAPLUS
4-Piperidinecarboxamide, 1-{6-{4-{[2-(1-methylethyl)phenyl}thio}-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS

388117-71-3 CAPLUS
1-Piperazinecarboxylic scid, 4-[6-[4-([2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]-, ethyl ester (9CI) (CA INDEX

388117-72-4 CAPLUS
1-Piperazineacetic acid, 4-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3(trifluoromethyl)phenyl]-4-pyrimidinyl]-, ethyl ester (9CI) (CA INDEX

388117-73-5 CAPLUS
4-Pyrimidinamine, N-[3-(1H-imidazol-1-yl)propyl]-6-[4-([2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)

F<sub>3</sub>C N N

RN 388117-74-6 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

i-Pr F3C NNNN CO2

RN 388117-75-7 CAPLUS
CN 3-Piperidinecarboxylic acid, 1-[6-[4-[(2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

F3C N N N CO2H

RN 388117-76-8 CAPLUS
CN Pyrimidine, 4-[4-[(2-(1-methylethyl)phenyl]thio]-3(trifluoromethyl)phenyl]-6-[4-(2-pyridinyl)-1-piperazinyl]- (9CI) (CA
INDEX NAME)

L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)

CP3

RN 388117-77-9 CAPLUS
CN 3-Piperidinecarboxamide, N,N-diethyl-1-[6-[4-[[2-[1-methylethyl]phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

F3C NEt2

RN 388117-78-0 CAPLUS
CN Pyrimidine, 4-[4-[(2-(1-methylethyl)phenyl]thio]-3(trifluoromethyl)phenyl]-6-[3-(1H-tetrazol-5-yl)-1-piperidinyl]- (9CI)
(CA INDEX NAME)

N S CF3

RN 388117-79-1 CAPLUS
Pyrimidine, 4-[4-{[2-{1-methylethyl}phenyl}thio]-3(trifluoromethyl)phenyl}-6-[4-{1H-tetrazol-5-yl}-1-piperidinyl}- (9CI)
(CA INDEX NAME)

L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)

F3C i-Pr

RN 388117-80-4 CAPLUS
CN 3-Piperidinemethanol, 1-[6-(4-[[2-(1-methylethyl)phenyl]thio]-3[(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

F3C CH2-OH

RN 388117-81-5 CAPLUS
CN 4-Piperidineethanol, 1-(6-{4-{[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

F3C N N CH2-CH2-OH

RN 388117-82-6 CAPLUS
CN Acetamide, N-[1-[6-[4-[[2-(1-methylethyl]phenyl]thio]-3(trifluoromethyl)phenyl]-4-pyrimidinyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)

i-Pr S CF<sub>3</sub>

RN 388117-83-7 CAPLUS
CN Pyrimidine, 4-[(2R)-2-(methoxymethyl)-1-pyrrolidinyl]-6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

CP3 i-Pr S S

RN 388117-84-8 CAPLUS
CN 3-Pyrrolidinol, 1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3(trifluoromethyl)phenyl]-4-pyrimidinyl]-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry

ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)

388117-85-9 CAPLUS
Carbamic acid, [1-[6-[4-{[2-(1-methylethyl)phenyl]thio]-3tirfluoromethyl)phenyl]-4-pyrimidinyl}-3-pyrrolidinyl}-,
1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

388117-86-0 CAPLUS
4-Pyrimidinamine, N-methyl-N-(1-methylethyl)-6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)

RN 388117-87-1 CAPLUS CN 4-Pyrimidinamine, N-ethyl-N-methyl-6-(4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

REFERENCE COUNT:

FORMAT

THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

L4 ANSWER 5 0F 6
ACCESSION NUMBER:
DOCUMENT NUMBER:
1992:612432 CAPLUS
117:212432

Studies on cerebral protective agents. I. Novel
4-arylpyrimidine derivatives with anti-anoxic and
anti-lipid peroxidation activities
AUTHOR(S):
Kuno, Ateushi, Suglyame, Yoshie; Katsuta, Kiyotaka;
Kamitani, Toshiharu; Taksaugi, Hisashi
New Drug Res. Lab., Pujiaswa Pharm. Co., Ltd., Osaka,
532, Japan
Chemical & Pharmaceutical Bulletin (1992), 40(6),
1452-61
CODEN: CPBTAL; ISSN: 0009-2363
Journal
LANGUAGE:
G1

LANGUAGE:

AB Novel 4-arylpyrimidine derivs. were synthesized by the oxidn. of 4-aryl-1,4-dihydropyrimidines, and their effects on anti-anoxic (AA) activity in mice and anti-lipid peroxidn. (ALP) activity in rat brain mitochondria were investigated. Among these compds. Et 6-methyl-2-phenyl-4-(4-pyridyl)-5-pyrimidinecarboxylate (I, R = 4-pyridyl) has AA activity (10 mg/kg, i.p.) and Et 6-methyl-4-(3-nitrophenyl)-2-phenyl-5-pyrimidinecarboxylate (I, R = 3-02NC6H4) has ALP activity (73% inhibition at 10-5 g/mL). The latter compd. (100 mg/kg, i.p.) was also effective on arachidonate-induced cerebral edema in rata with comparable potency to that of vitamin E.

101233-67-0 (APLUS)
RN 103233-67-0 (APLUS)
CN 5-Pyrimidinecarboxylic acid, 4-(2-(4-chlorophenyl)thiolphenyl]-6-methyl-2-phenyl-, ethyl ester (9CI) (CA INDEX NAME)

Habte

L4 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2003 ACS

PRIORITY APPLN. INFO.:

GI

19850927

EP 1985-306880

L4 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1986:572492 CAPLUS
DOCUMENT NUMBER: 105:172492 DS. 172492
INVENTOR(S): Takay, Takao; Takasuj, Hisashi; Kuno, Atsushi; Sugiyama, Yoshie
PATENT ASSIGNEE(S): FUjisawa Pharmaceutical Co., Ltd., Japan
BOCUMENT TYPE: ENT. PAT. Appl., 192 pp.
CODEN: EPXXDW
DOCUMENT TYPE: English
PAMILY ACC. NUM. COUNT 1
PATENT INFORMATION: FAMILY ACC. NUM. COUNT: PATENT INFORMATION: PATENT NO. APPLICATION NO. DATE KIND DATE 19860129 EP 169712 EP 169712 EP 169712 EP 1985-305143 19850718 A2 A3 B1 19861203 EP 169712 A3 1 EP 169712 B1 1 R: AT, BE, CH, DE, AT, SB097 E L, AT, SB097 E 19901212 19901212
, FR. GB, TT, LI, LU, NL, SE
19871006
 US 1985-753912
19860625
 ZA 1985-5369
19860120
 NO 1985-2869
19860120
 NO 1985-2279
19860120
 DK 1985-3279
19861016
 ES 1985-545347
19901215
 AT 1985-305143
19860123
 AU 1985-45202
19860226
 JP 1985-160784 19850711 19850716 19850717 19850718 19850718 19860120 DK 1985-3279
19861016 ES 1985-545347
19901215 AT 1985-305143
19860123 AU 1985-45202
19860226 JP 1985-160784
19960528 ZA 1985-779043
19860528 ZA 1985-779043
19860402 PI 1985-30698
19961126
19901215 AT 1985-306880
1996126
19901215 AT 1985-30681
19860402 DK 1985-34436
19860402 DK 1985-34436
19860402 DK 1985-3453
19870316 ES 1985-347419
19860506 B 1984-24711
GB 1985-9623
GB 1984-24711
GB 1985-9623
GB 1985-9623 19850718 19850718 19850719 19850719 19850923 19850924 19850926 19850927

ANSWER 6 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)

AB Pyrimidines I (R = substituted ary1; K1 = 00000, alkanoy), etc.; R2 = H, ary1, alky1, etc.; R3 = alky1, ary1) were prepd., and they showed their usefulness in the treatment of cerebrovescular diseases. Dihydropyrimidine deriv. II was heated with MnO2 to give I (R = 0000).

Dihydropyrimidine deriv. II was heated with MnO2 to give 1 (x 4-pyridyl,
R1 = CO1Et, R2 = Me, R3 = Ph). II was prepd. from an .alpha.(arylmethylene)acetoacetate eater and an amidine.
II 103293-67-09
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, for treatment of cerebrovascular disease)
RN 103293-67-0 CAPLUS
CN 5-Pyrimidinecarboxylic acid,
4-[2-[(4-chlorophenyl]thio]phenyl]-6-methyl-2phenyl-, ethyl ester (9CI) (CA INDEX NAME)

Habte

=> log y COST IN U.S. DOLLARS SINCE FILE TOTAL ENTRY SESSION FULL ESTIMATED COST 28.05

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE TOTAL ENTRY SESSION -3.91 CA SUBSCRIBER PRICE -3.91

176.41

STN INTERNATIONAL LOGOFF AT 17:34:56 ON 10 APR 2003

Habte